
Keywords: IgE کل; Childhood asthma; Efficacy; Omalizumab; Safety evaluation; Total IgE; AEs; adverse events; ER; emergency room; EOT; end of the treatment period; ELISA; enzyme-linked immunosorbent assay; FP; fluticasone propionate; FEV1; forced expiratory volume in 1Â s;